iNOS inhibitors have the potential to block excessive NO synthesis in tumor cells and have shown promise in preclinical studies by inhibiting tumor proliferation and enhancing sensitivity to radiotherapy and chemotherapy [191]. The gene discussed is NOS2; the disease is neoplasm.